Livzon Pharmaceutical Group has been identified as an investor by MIT spinout Elicio Therapeutics, which just completed a series B round that takes its total financing to $63m.

Elicio Therapeutics, a US-based immuno-oncology therapy spinout of Massachusetts Institute of Technology (MIT), closed a $33m series B round on Wednesday, naming pharmaceutical group Livzon among its investors.
The company said investment firm Clal Biotechnology Industries and life sciences-focused venture capital firm Efung Capital are also part of its investor base, without confirming their participation in the latest round.
Elicio is developing cancer immunotherapies aimed at the lymph node, utilising its propietary Amphiphile platform, which allows immunogens and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?